Effect of Liposome Bupivacaine Serratus Plane Block on Postoperative Hyperalgesia and Chronic Post-surgical Pain in Patients Undergoing Radical Mastectomy
Not yet recruitingPhase 1, Phase 2NCT07289178
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Radical mastectomy is currently the mainstream surgical treatment for breast cancer. Patients often experience significant postoperative pain, and some may develop chronic pain. General anesthesia is commonly used, with remifentanil being the most frequently used intraoperative analgesic. However, prolonged high-dose use of remifentanil can induce opioid-induced hyperalgesia (OIH). Previous studies have shown that serratus anterior plane block can reduce acute postoperative pain after radical mastectomy, but it remains unclear whether it can reduce postoperative pain sensitization and the incidence of chronic pain. Liposomal bupivacaine is a new long-acting local anesthetic with an effect lasting up to 72 hours. This study aims to investigate the effect of liposomal bupivacaine serratus anterior plane block on postoperative pain sensitization and chronic pain in patients undergoing radical mastectomy, providing a reference for clinical treatment. The study includes 120 participants. A tactile measurement kit is used to measure the mechanical pain threshold around the surgical incision preoperatively and at 24 and 48 hours postoperatively, as well as postoperative persistent pain scores at 7 days, 1 month, 3 months, and 6 months. The data will then be analyzed to draw conclusions.
Study details
- Official title
- Effect of Liposome Bupivacaine Serratus Plane Block on Postoperative Hyperalgesia and Chronic Post-surgical Pain in Patients Undergoing Radical Mastectomy
- Conditions
- Serratus Plane Block
- Postoperative Hyperalgesia
- Chronic Post-surgical Pain
- Liposomal Bupivacaine
- Radical Mastectomy Surgery
- Interventions
- Procedure: Serratus Plane block (single injection)
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start date
- 2026-01-01
- Primary completion
- 2026-10-01
- Sex
- Female
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: Select patients scheduled for elective radical mastectomy for breast cancer under general anesthesia, ASA grade I-IV, aged 18-80 years. Exclusion Criteria: Allergy to the anesthetics used, infection at the puncture site, history of chronic pain and current use of opioid analgesics, history of chest surgery or trauma, drug or alcohol dependence, neurological or psychiatric disorders, severe hepatic or renal insufficiency, pregnancy, body mass index (BMI) greater than 30 kg/m².
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07289178